198 related articles for article (PubMed ID: 23357778)
21. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.
Raynaud C; Lanéelle MA; Senaratne RH; Draper P; Lanéelle G; Daffé M
Microbiology (Reading); 1999 Jun; 145 ( Pt 6)():1359-1367. PubMed ID: 10411262
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
Che Y; Bo D; Lin X; Chen T; He T; Lin Y
BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
[TBL] [Abstract][Full Text] [Related]
23. A novel inexpensive electrochemical sensor for pyrazinoic acid as a potential tool for the identification of pyrazinamide-resistant
Rueda D; Furukawa R; Fuentes P; Comina G; Rey De Castro NG; Requena D; Gilman RH; Sheen P; Zimic M
Int J Mycobacteriol; 2018; 7(3):275-281. PubMed ID: 30198510
[TBL] [Abstract][Full Text] [Related]
24. Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of
Tam KK; Leung KS; Siu GK; Chang KC; Wong SS; Ho PL; Leung EK; Yam WC
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31189582
[TBL] [Abstract][Full Text] [Related]
25. Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs.
Lenaerts AJ; Johnson CM; Marrieta KS; Gruppo V; Orme IM
Int J Antimicrob Agents; 2005 Aug; 26(2):152-8. PubMed ID: 15953708
[TBL] [Abstract][Full Text] [Related]
26. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?
Pullan ST; Allnutt JC; Devine R; Hatch KA; Jeeves RE; Hendon-Dunn CL; Marsh PD; Bacon J
BMC Infect Dis; 2016 May; 16():205. PubMed ID: 27184366
[TBL] [Abstract][Full Text] [Related]
27. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
[TBL] [Abstract][Full Text] [Related]
28. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Permar S; Sun Z
J Med Microbiol; 2002 Jan; 51(1):42-49. PubMed ID: 11800471
[TBL] [Abstract][Full Text] [Related]
29. Impact of the host environment on the antitubercular action of pyrazinamide.
Lamont EA; Baughn AD
EBioMedicine; 2019 Nov; 49():374-380. PubMed ID: 31669220
[TBL] [Abstract][Full Text] [Related]
30. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.
Jonmalung J; Prammananan T; Leechawengwongs M; Chaiprasert A
BMC Microbiol; 2010 Aug; 10():223. PubMed ID: 20727143
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
32. Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide.
Yang J; Liu Y; Bi J; Cai Q; Liao X; Li W; Guo C; Zhang Q; Lin T; Zhao Y; Wang H; Liu J; Zhang X; Lin D
Mol Microbiol; 2015 Mar; 95(5):791-803. PubMed ID: 25430994
[TBL] [Abstract][Full Text] [Related]
33. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
Hagiwara E; Suido Y; Asaoka M; Katano T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Ogura T
J Infect Chemother; 2019 Dec; 25(12):1026-1030. PubMed ID: 31229376
[TBL] [Abstract][Full Text] [Related]
34. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.
Cheng SJ; Thibert L; Sanchez T; Heifets L; Zhang Y
Antimicrob Agents Chemother; 2000 Mar; 44(3):528-32. PubMed ID: 10681313
[TBL] [Abstract][Full Text] [Related]
35. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
Speirs RJ; Welch JT; Cynamon MH
Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
[TBL] [Abstract][Full Text] [Related]
36. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
37. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis.
Stoffels K; Mathys V; Fauville-Dufaux M; Wintjens R; Bifani P
Antimicrob Agents Chemother; 2012 Oct; 56(10):5186-93. PubMed ID: 22825123
[TBL] [Abstract][Full Text] [Related]
38. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
39. Metabolic disposition of pyrazinamide in the rat: identification of a novel in vivo metabolite common to both rat and human.
Whitehouse LW; Lodge BA; By AW; Thomas BH
Biopharm Drug Dispos; 1987; 8(4):307-18. PubMed ID: 3620591
[TBL] [Abstract][Full Text] [Related]
40. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Masood N; Nadeem T; Khan AS; Afzal MT
BMC Infect Dis; 2019 Feb; 19(1):116. PubMed ID: 30728001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
